Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Transplantation for Stiff Person Syndrome (SPS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of Stiff-person Syndrome and~   * Age between 18 and 60 years old~  * Failure of medically tolerable doses (20-40 mg/day) of diazepam~  * Failure of either intravenous immunoglobulin (IVIg) and or plasmapheresis~  * Stiffness in the axial muscles, prominently in the abdominal and thoracolumbar paraspinal muscle leading to a fixed deformity (hyperlordosis)~  * Superimposed painful spasms precipitated by unexpected noises, emotional stress, tactile stimuli~  * Confirmation of the continuous motor unit activity in agonist and antagonist muscles by electromyography when off diazepam and anti-spasmatic medications~  * Absence of neurological or cognitive impairments that could explain the stiffness~  * Inability to run or walk, or abnormal gait~2. Diagnosis of a SPS variant- Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM) defined as:~   Acute onset of painful rigidity and muscle spasms in the limbs and trunk~  * Brainstem dysfunction (nystagmus, opsoclonus, ophthalmoparesis, deafness, dysarthria, dysphagia)~  * Profound autonomic disturbance.~  * Positive serology for GAD65 (or amphiphysin) autoantibodies, assessed by immunocytochemistry, western blot or radioimmunoassay (\>1000 u/ml)~  * MRI may show increased signal intensity throughout the spinal cord and the brainstem~3. Diagnosis of a SPS variant - anti-GAD positive cerebellar ataxia~   * Subacute or chronic onset of cerebellar symptoms-gait or limb ataxia, dysarthria, nystagmus~  * Positive serology for GAD65 (or amphiphysin) autoantibodies, assessed by immunocytochemistry, western blot or radioimmunoassay (\>1000 u/ml)~  * Anti-GAD antibody in cerebrospinal fluid~  * Abnormal MRI imaging of brainstem or cerebellum other than cerebellar atrophy~  * Negative history of toxin or alcohol~  * Absence of Vitamin B12 or Vitamin E deficiency~  * Absence of positive HIV, syphilis or whipple disease~  * Absence of consanguinity, positive family history for ataxia or positive genetic screen for spinocerebellar ataxia (SCA) 1, SCA 2, SCA 3, SCA 6, SCA 7 or SCA 8 mutation~Exclusion Criteria:~* Current or prior history of a malignancy or paraneoplastic syndrome~* Inability to sign and understand consent and be compliant with treatment~* Positive pregnancy test~* Inability to or comprehend irreversible sterility as a possible side effect~* Amphiphysin antibody positive~* Left ventricular ejection fraction (LVEF) \< 45% or ischemic coronary artery disease on dobutamine stress echocardiogram~* Diffusing capacity of the lungs for carbon monoxide (DLCO) \< 60% predicted~* Serum creatinine \> 2.0 mg/dl~* Bilirubin \>2.0 mg/dl~* Platelet count \< 100,000 / ul, white blood cell count (WBC) \< 1,500 cells/mm3~* History of toxin or alcohol abuse~* History of Vitamin B12 or Vitamin E deficiency~* Positive HIV, syphilis, or whipple disease~* Consanguinity, positive family history for ataxia or positive genetic screen for SCA1, SCA2, SCA3, SCA6, SCA 7 or SCA8 mutation (if ataxia present)~* Absence of at least one SPS associated antibody such as anti-GAD, or gamma-aminobutyric acid (GABA)-A receptor associated protein, or synaptophysin, or gephyrin, or GABA-transaminase

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Hematopoietic Stem Cell Transplantation (Type: EXPERIMENTAL): The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5, 1.0 mg/kg on days -4 and -3, and then 1.5 mg/kg on days -2 and -1. Methylprednisolone 1000 mg will be infused intravenously before each dose of rATG. Autologous hematopoietic stem cells will be infused intravenously on day 0. A granulocyte-colony stimulating factor (G-CSF) 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment. Intravenous Rituxan (500mg) will be administered on days -6 and +1.

Based on this trial design, predict the completion outcome and termination type (if applicable).